Global Inactivated Influenza Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 109

Published Date: 23 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Inactivated Influenza Vaccine market size was valued at USD 7192.4 million in 2023 and is forecast to a readjusted size of USD 10170 million by 2030 with a CAGR of 5.1% during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Inactivated Influenza Vaccine industry chain, the market status of Children (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), Adolescence (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Inactivated Influenza Vaccine.

Regionally, the report analyzes the Inactivated Influenza Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Inactivated Influenza Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Inactivated Influenza Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Inactivated Influenza Vaccine industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Inactivated Influenza Vaccine market.

Regional Analysis: The report involves examining the Inactivated Influenza Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Inactivated Influenza Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Inactivated Influenza Vaccine:
Company Analysis: Report covers individual Inactivated Influenza Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Inactivated Influenza Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Children, Adolescence).

Technology Analysis: Report covers specific technologies relevant to Inactivated Influenza Vaccine. It assesses the current state, advancements, and potential future developments in Inactivated Influenza Vaccine areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Inactivated Influenza Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Inactivated Influenza Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine

Market segment by Application
Children
Adolescence
Adults
Elderly

Major players covered
CSL Limited
GSK
Sanofi Pasteur
Viatris
Hualan Biological
AstraZeneca
Sinovac Biotech
Aleph Biomedical
Abbott Laboratories
Novartis International
Changchun Institute of Biological
BCHT
Jiangsu GDK
KM Biologics

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Inactivated Influenza Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Inactivated Influenza Vaccine, with price, sales, revenue and global market share of Inactivated Influenza Vaccine from 2019 to 2024.
Chapter 3, the Inactivated Influenza Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inactivated Influenza Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Inactivated Influenza Vaccine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Inactivated Influenza Vaccine.
Chapter 14 and 15, to describe Inactivated Influenza Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Inactivated Influenza Vaccine
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Inactivated Influenza Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Trivalent Influenza Vaccine
        1.3.3 Quadrivalent Influenza Vaccine
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Inactivated Influenza Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Children
        1.4.3 Adolescence
        1.4.4 Adults
        1.4.5 Elderly
    1.5 Global Inactivated Influenza Vaccine Market Size & Forecast
        1.5.1 Global Inactivated Influenza Vaccine Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Inactivated Influenza Vaccine Sales Quantity (2019-2030)
        1.5.3 Global Inactivated Influenza Vaccine Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 CSL Limited
        2.1.1 CSL Limited Details
        2.1.2 CSL Limited Major Business
        2.1.3 CSL Limited Inactivated Influenza Vaccine Product and Services
        2.1.4 CSL Limited Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 CSL Limited Recent Developments/Updates
    2.2 GSK
        2.2.1 GSK Details
        2.2.2 GSK Major Business
        2.2.3 GSK Inactivated Influenza Vaccine Product and Services
        2.2.4 GSK Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 GSK Recent Developments/Updates
    2.3 Sanofi Pasteur
        2.3.1 Sanofi Pasteur Details
        2.3.2 Sanofi Pasteur Major Business
        2.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Product and Services
        2.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Sanofi Pasteur Recent Developments/Updates
    2.4 Viatris
        2.4.1 Viatris Details
        2.4.2 Viatris Major Business
        2.4.3 Viatris Inactivated Influenza Vaccine Product and Services
        2.4.4 Viatris Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Viatris Recent Developments/Updates
    2.5 Hualan Biological
        2.5.1 Hualan Biological Details
        2.5.2 Hualan Biological Major Business
        2.5.3 Hualan Biological Inactivated Influenza Vaccine Product and Services
        2.5.4 Hualan Biological Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Hualan Biological Recent Developments/Updates
    2.6 AstraZeneca
        2.6.1 AstraZeneca Details
        2.6.2 AstraZeneca Major Business
        2.6.3 AstraZeneca Inactivated Influenza Vaccine Product and Services
        2.6.4 AstraZeneca Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 AstraZeneca Recent Developments/Updates
    2.7 Sinovac Biotech
        2.7.1 Sinovac Biotech Details
        2.7.2 Sinovac Biotech Major Business
        2.7.3 Sinovac Biotech Inactivated Influenza Vaccine Product and Services
        2.7.4 Sinovac Biotech Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Sinovac Biotech Recent Developments/Updates
    2.8 Aleph Biomedical
        2.8.1 Aleph Biomedical Details
        2.8.2 Aleph Biomedical Major Business
        2.8.3 Aleph Biomedical Inactivated Influenza Vaccine Product and Services
        2.8.4 Aleph Biomedical Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Aleph Biomedical Recent Developments/Updates
    2.9 Abbott Laboratories
        2.9.1 Abbott Laboratories Details
        2.9.2 Abbott Laboratories Major Business
        2.9.3 Abbott Laboratories Inactivated Influenza Vaccine Product and Services
        2.9.4 Abbott Laboratories Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Abbott Laboratories Recent Developments/Updates
    2.10 Novartis International
        2.10.1 Novartis International Details
        2.10.2 Novartis International Major Business
        2.10.3 Novartis International Inactivated Influenza Vaccine Product and Services
        2.10.4 Novartis International Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Novartis International Recent Developments/Updates
    2.11 Changchun Institute of Biological
        2.11.1 Changchun Institute of Biological Details
        2.11.2 Changchun Institute of Biological Major Business
        2.11.3 Changchun Institute of Biological Inactivated Influenza Vaccine Product and Services
        2.11.4 Changchun Institute of Biological Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Changchun Institute of Biological Recent Developments/Updates
    2.12 BCHT
        2.12.1 BCHT Details
        2.12.2 BCHT Major Business
        2.12.3 BCHT Inactivated Influenza Vaccine Product and Services
        2.12.4 BCHT Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 BCHT Recent Developments/Updates
    2.13 Jiangsu GDK
        2.13.1 Jiangsu GDK Details
        2.13.2 Jiangsu GDK Major Business
        2.13.3 Jiangsu GDK Inactivated Influenza Vaccine Product and Services
        2.13.4 Jiangsu GDK Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 Jiangsu GDK Recent Developments/Updates
    2.14 KM Biologics
        2.14.1 KM Biologics Details
        2.14.2 KM Biologics Major Business
        2.14.3 KM Biologics Inactivated Influenza Vaccine Product and Services
        2.14.4 KM Biologics Inactivated Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.14.5 KM Biologics Recent Developments/Updates

3 Competitive Environment: Inactivated Influenza Vaccine by Manufacturer
    3.1 Global Inactivated Influenza Vaccine Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Inactivated Influenza Vaccine Revenue by Manufacturer (2019-2024)
    3.3 Global Inactivated Influenza Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Inactivated Influenza Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Inactivated Influenza Vaccine Manufacturer Market Share in 2023
        3.4.2 Top 6 Inactivated Influenza Vaccine Manufacturer Market Share in 2023
    3.5 Inactivated Influenza Vaccine Market: Overall Company Footprint Analysis
        3.5.1 Inactivated Influenza Vaccine Market: Region Footprint
        3.5.2 Inactivated Influenza Vaccine Market: Company Product Type Footprint
        3.5.3 Inactivated Influenza Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Inactivated Influenza Vaccine Market Size by Region
        4.1.1 Global Inactivated Influenza Vaccine Sales Quantity by Region (2019-2030)
        4.1.2 Global Inactivated Influenza Vaccine Consumption Value by Region (2019-2030)
        4.1.3 Global Inactivated Influenza Vaccine Average Price by Region (2019-2030)
    4.2 North America Inactivated Influenza Vaccine Consumption Value (2019-2030)
    4.3 Europe Inactivated Influenza Vaccine Consumption Value (2019-2030)
    4.4 Asia-Pacific Inactivated Influenza Vaccine Consumption Value (2019-2030)
    4.5 South America Inactivated Influenza Vaccine Consumption Value (2019-2030)
    4.6 Middle East and Africa Inactivated Influenza Vaccine Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Inactivated Influenza Vaccine Sales Quantity by Type (2019-2030)
    5.2 Global Inactivated Influenza Vaccine Consumption Value by Type (2019-2030)
    5.3 Global Inactivated Influenza Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Inactivated Influenza Vaccine Sales Quantity by Application (2019-2030)
    6.2 Global Inactivated Influenza Vaccine Consumption Value by Application (2019-2030)
    6.3 Global Inactivated Influenza Vaccine Average Price by Application (2019-2030)

7 North America
    7.1 North America Inactivated Influenza Vaccine Sales Quantity by Type (2019-2030)
    7.2 North America Inactivated Influenza Vaccine Sales Quantity by Application (2019-2030)
    7.3 North America Inactivated Influenza Vaccine Market Size by Country
        7.3.1 North America Inactivated Influenza Vaccine Sales Quantity by Country (2019-2030)
        7.3.2 North America Inactivated Influenza Vaccine Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Inactivated Influenza Vaccine Sales Quantity by Type (2019-2030)
    8.2 Europe Inactivated Influenza Vaccine Sales Quantity by Application (2019-2030)
    8.3 Europe Inactivated Influenza Vaccine Market Size by Country
        8.3.1 Europe Inactivated Influenza Vaccine Sales Quantity by Country (2019-2030)
        8.3.2 Europe Inactivated Influenza Vaccine Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Inactivated Influenza Vaccine Market Size by Region
        9.3.1 Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Inactivated Influenza Vaccine Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Inactivated Influenza Vaccine Sales Quantity by Type (2019-2030)
    10.2 South America Inactivated Influenza Vaccine Sales Quantity by Application (2019-2030)
    10.3 South America Inactivated Influenza Vaccine Market Size by Country
        10.3.1 South America Inactivated Influenza Vaccine Sales Quantity by Country (2019-2030)
        10.3.2 South America Inactivated Influenza Vaccine Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Inactivated Influenza Vaccine Market Size by Country
        11.3.1 Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Inactivated Influenza Vaccine Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Inactivated Influenza Vaccine Market Drivers
    12.2 Inactivated Influenza Vaccine Market Restraints
    12.3 Inactivated Influenza Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Inactivated Influenza Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Inactivated Influenza Vaccine
    13.3 Inactivated Influenza Vaccine Production Process
    13.4 Inactivated Influenza Vaccine Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Inactivated Influenza Vaccine Typical Distributors
    14.3 Inactivated Influenza Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Inactivated Influenza Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Inactivated Influenza Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. CSL Limited Basic Information, Manufacturing Base and Competitors
    Table 4. CSL Limited Major Business
    Table 5. CSL Limited Inactivated Influenza Vaccine Product and Services
    Table 6. CSL Limited Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. CSL Limited Recent Developments/Updates
    Table 8. GSK Basic Information, Manufacturing Base and Competitors
    Table 9. GSK Major Business
    Table 10. GSK Inactivated Influenza Vaccine Product and Services
    Table 11. GSK Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. GSK Recent Developments/Updates
    Table 13. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
    Table 14. Sanofi Pasteur Major Business
    Table 15. Sanofi Pasteur Inactivated Influenza Vaccine Product and Services
    Table 16. Sanofi Pasteur Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. Sanofi Pasteur Recent Developments/Updates
    Table 18. Viatris Basic Information, Manufacturing Base and Competitors
    Table 19. Viatris Major Business
    Table 20. Viatris Inactivated Influenza Vaccine Product and Services
    Table 21. Viatris Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. Viatris Recent Developments/Updates
    Table 23. Hualan Biological Basic Information, Manufacturing Base and Competitors
    Table 24. Hualan Biological Major Business
    Table 25. Hualan Biological Inactivated Influenza Vaccine Product and Services
    Table 26. Hualan Biological Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. Hualan Biological Recent Developments/Updates
    Table 28. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 29. AstraZeneca Major Business
    Table 30. AstraZeneca Inactivated Influenza Vaccine Product and Services
    Table 31. AstraZeneca Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. AstraZeneca Recent Developments/Updates
    Table 33. Sinovac Biotech Basic Information, Manufacturing Base and Competitors
    Table 34. Sinovac Biotech Major Business
    Table 35. Sinovac Biotech Inactivated Influenza Vaccine Product and Services
    Table 36. Sinovac Biotech Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 37. Sinovac Biotech Recent Developments/Updates
    Table 38. Aleph Biomedical Basic Information, Manufacturing Base and Competitors
    Table 39. Aleph Biomedical Major Business
    Table 40. Aleph Biomedical Inactivated Influenza Vaccine Product and Services
    Table 41. Aleph Biomedical Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 42. Aleph Biomedical Recent Developments/Updates
    Table 43. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
    Table 44. Abbott Laboratories Major Business
    Table 45. Abbott Laboratories Inactivated Influenza Vaccine Product and Services
    Table 46. Abbott Laboratories Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 47. Abbott Laboratories Recent Developments/Updates
    Table 48. Novartis International Basic Information, Manufacturing Base and Competitors
    Table 49. Novartis International Major Business
    Table 50. Novartis International Inactivated Influenza Vaccine Product and Services
    Table 51. Novartis International Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 52. Novartis International Recent Developments/Updates
    Table 53. Changchun Institute of Biological Basic Information, Manufacturing Base and Competitors
    Table 54. Changchun Institute of Biological Major Business
    Table 55. Changchun Institute of Biological Inactivated Influenza Vaccine Product and Services
    Table 56. Changchun Institute of Biological Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 57. Changchun Institute of Biological Recent Developments/Updates
    Table 58. BCHT Basic Information, Manufacturing Base and Competitors
    Table 59. BCHT Major Business
    Table 60. BCHT Inactivated Influenza Vaccine Product and Services
    Table 61. BCHT Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 62. BCHT Recent Developments/Updates
    Table 63. Jiangsu GDK Basic Information, Manufacturing Base and Competitors
    Table 64. Jiangsu GDK Major Business
    Table 65. Jiangsu GDK Inactivated Influenza Vaccine Product and Services
    Table 66. Jiangsu GDK Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 67. Jiangsu GDK Recent Developments/Updates
    Table 68. KM Biologics Basic Information, Manufacturing Base and Competitors
    Table 69. KM Biologics Major Business
    Table 70. KM Biologics Inactivated Influenza Vaccine Product and Services
    Table 71. KM Biologics Inactivated Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 72. KM Biologics Recent Developments/Updates
    Table 73. Global Inactivated Influenza Vaccine Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 74. Global Inactivated Influenza Vaccine Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 75. Global Inactivated Influenza Vaccine Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 76. Market Position of Manufacturers in Inactivated Influenza Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 77. Head Office and Inactivated Influenza Vaccine Production Site of Key Manufacturer
    Table 78. Inactivated Influenza Vaccine Market: Company Product Type Footprint
    Table 79. Inactivated Influenza Vaccine Market: Company Product Application Footprint
    Table 80. Inactivated Influenza Vaccine New Market Entrants and Barriers to Market Entry
    Table 81. Inactivated Influenza Vaccine Mergers, Acquisition, Agreements, and Collaborations
    Table 82. Global Inactivated Influenza Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 83. Global Inactivated Influenza Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 84. Global Inactivated Influenza Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 85. Global Inactivated Influenza Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 86. Global Inactivated Influenza Vaccine Average Price by Region (2019-2024) & (US$/Unit)
    Table 87. Global Inactivated Influenza Vaccine Average Price by Region (2025-2030) & (US$/Unit)
    Table 88. Global Inactivated Influenza Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 89. Global Inactivated Influenza Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 90. Global Inactivated Influenza Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 91. Global Inactivated Influenza Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 92. Global Inactivated Influenza Vaccine Average Price by Type (2019-2024) & (US$/Unit)
    Table 93. Global Inactivated Influenza Vaccine Average Price by Type (2025-2030) & (US$/Unit)
    Table 94. Global Inactivated Influenza Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 95. Global Inactivated Influenza Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 96. Global Inactivated Influenza Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 97. Global Inactivated Influenza Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 98. Global Inactivated Influenza Vaccine Average Price by Application (2019-2024) & (US$/Unit)
    Table 99. Global Inactivated Influenza Vaccine Average Price by Application (2025-2030) & (US$/Unit)
    Table 100. North America Inactivated Influenza Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 101. North America Inactivated Influenza Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 102. North America Inactivated Influenza Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 103. North America Inactivated Influenza Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 104. North America Inactivated Influenza Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 105. North America Inactivated Influenza Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 106. North America Inactivated Influenza Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 107. North America Inactivated Influenza Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 108. Europe Inactivated Influenza Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 109. Europe Inactivated Influenza Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 110. Europe Inactivated Influenza Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 111. Europe Inactivated Influenza Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 112. Europe Inactivated Influenza Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 113. Europe Inactivated Influenza Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 114. Europe Inactivated Influenza Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 115. Europe Inactivated Influenza Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 116. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 117. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 118. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 119. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 120. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 121. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 122. Asia-Pacific Inactivated Influenza Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 123. Asia-Pacific Inactivated Influenza Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 124. South America Inactivated Influenza Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 125. South America Inactivated Influenza Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 126. South America Inactivated Influenza Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 127. South America Inactivated Influenza Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 128. South America Inactivated Influenza Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 129. South America Inactivated Influenza Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 130. South America Inactivated Influenza Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 131. South America Inactivated Influenza Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 132. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 133. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 134. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 135. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 136. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 137. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 138. Middle East & Africa Inactivated Influenza Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 139. Middle East & Africa Inactivated Influenza Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 140. Inactivated Influenza Vaccine Raw Material
    Table 141. Key Manufacturers of Inactivated Influenza Vaccine Raw Materials
    Table 142. Inactivated Influenza Vaccine Typical Distributors
    Table 143. Inactivated Influenza Vaccine Typical Customers
List of Figures
    Figure 1. Inactivated Influenza Vaccine Picture
    Figure 2. Global Inactivated Influenza Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Inactivated Influenza Vaccine Consumption Value Market Share by Type in 2023
    Figure 4. Trivalent Influenza Vaccine Examples
    Figure 5. Quadrivalent Influenza Vaccine Examples
    Figure 6. Global Inactivated Influenza Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 7. Global Inactivated Influenza Vaccine Consumption Value Market Share by Application in 2023
    Figure 8. Children Examples
    Figure 9. Adolescence Examples
    Figure 10. Adults Examples
    Figure 11. Elderly Examples
    Figure 12. Global Inactivated Influenza Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Inactivated Influenza Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Inactivated Influenza Vaccine Sales Quantity (2019-2030) & (K Units)
    Figure 15. Global Inactivated Influenza Vaccine Average Price (2019-2030) & (US$/Unit)
    Figure 16. Global Inactivated Influenza Vaccine Sales Quantity Market Share by Manufacturer in 2023
    Figure 17. Global Inactivated Influenza Vaccine Consumption Value Market Share by Manufacturer in 2023
    Figure 18. Producer Shipments of Inactivated Influenza Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 19. Top 3 Inactivated Influenza Vaccine Manufacturer (Consumption Value) Market Share in 2023
    Figure 20. Top 6 Inactivated Influenza Vaccine Manufacturer (Consumption Value) Market Share in 2023
    Figure 21. Global Inactivated Influenza Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 22. Global Inactivated Influenza Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 23. North America Inactivated Influenza Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 24. Europe Inactivated Influenza Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 25. Asia-Pacific Inactivated Influenza Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 26. South America Inactivated Influenza Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 27. Middle East & Africa Inactivated Influenza Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 28. Global Inactivated Influenza Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 29. Global Inactivated Influenza Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 30. Global Inactivated Influenza Vaccine Average Price by Type (2019-2030) & (US$/Unit)
    Figure 31. Global Inactivated Influenza Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 32. Global Inactivated Influenza Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 33. Global Inactivated Influenza Vaccine Average Price by Application (2019-2030) & (US$/Unit)
    Figure 34. North America Inactivated Influenza Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 35. North America Inactivated Influenza Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 36. North America Inactivated Influenza Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 37. North America Inactivated Influenza Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 38. United States Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 39. Canada Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 40. Mexico Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 41. Europe Inactivated Influenza Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 42. Europe Inactivated Influenza Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 43. Europe Inactivated Influenza Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 44. Europe Inactivated Influenza Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 45. Germany Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 46. France Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 47. United Kingdom Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 48. Russia Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. Italy Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 50. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 51. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 52. Asia-Pacific Inactivated Influenza Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 53. Asia-Pacific Inactivated Influenza Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 54. China Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 55. Japan Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 56. Korea Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 57. India Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Southeast Asia Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. Australia Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 60. South America Inactivated Influenza Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 61. South America Inactivated Influenza Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 62. South America Inactivated Influenza Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 63. South America Inactivated Influenza Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 64. Brazil Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 65. Argentina Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 66. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 67. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 68. Middle East & Africa Inactivated Influenza Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 69. Middle East & Africa Inactivated Influenza Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 70. Turkey Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 71. Egypt Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 72. Saudi Arabia Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 73. South Africa Inactivated Influenza Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 74. Inactivated Influenza Vaccine Market Drivers
    Figure 75. Inactivated Influenza Vaccine Market Restraints
    Figure 76. Inactivated Influenza Vaccine Market Trends
    Figure 77. Porters Five Forces Analysis
    Figure 78. Manufacturing Cost Structure Analysis of Inactivated Influenza Vaccine in 2023
    Figure 79. Manufacturing Process Analysis of Inactivated Influenza Vaccine
    Figure 80. Inactivated Influenza Vaccine Industrial Chain
    Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 82. Direct Channel Pros & Cons
    Figure 83. Indirect Channel Pros & Cons
    Figure 84. Methodology
    Figure 85. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

CSL Limited
GSK
Sanofi Pasteur
Viatris
Hualan Biological
AstraZeneca
Sinovac Biotech
Aleph Biomedical
Abbott Laboratories
Novartis International
Changchun Institute of Biological
BCHT
Jiangsu GDK
KM Biologics

Related Reports

Global Inactivated Influenza Vaccine Supply, Demand and Key Producers, 2023-2029

Global Inactivated Influenza Vaccine Supply, Demand and Key Producers, 2023-2029

date 01 Sep 2023

date Pharma & Healthcare

The global Inactivated Influenza Vaccine market size is expected to reach $ 10170 million by 2029, rising at a market growth of 5.1% CAGR during the forecast period (2023-2029).

Global Inactivated Influenza Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Inactivated Influenza Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 01 Sep 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Inactivated Influenza Vaccine market size was valued at USD 7192.4 million in 2022 and is forecast to a readjusted size of USD 10170 million by 2029 with a CAGR of 5.1% during review period.

Product Tags

Trivalent Inactivated Influenza Vaccine

Inactivated Influenza Vaccine

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>